Drug
Cadonilimab
Cadonilimab: highest development phase Phase 3, developed by Akeso. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| Cadonilimab NCT07700979 | Phase 3 | Gastric / Gastroesophageal Junction Adenocarcinoma |
| Cadonilimab NCT05824494 | Phase 2 | Uterine Cervical Neoplasms |
Latest
Follow Cadonilimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.